Sutro Biopharma (STRO) Current Assets (2017 - 2025)

Sutro Biopharma has disclosed Current Assets across 9 years of filings, most recently posting $150.9 million for Q4 2025.

• Current Assets for Q4 2025 came in at $150.9 million, down 56.04% year-over-year; the trailing twelve-month figure through Dec 2025 was $150.9 million (down 56.04% YoY), and the FY2025 annual result was $150.9 million, down 56.04% from the prior year.
• Current Assets came in at $150.9 million for Q4 2025 at Sutro Biopharma, down from $182.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $443.5 million in Q2 2024 to a low of $150.9 million in Q4 2025.
• The 5-year median for Current Assets is $317.8 million (2022), against an average of $309.5 million.
• Across the five-year window, Current Assets jumped 108.7% in 2021 and plunged 56.04% in 2025, its largest moves.
• Sutro Biopharma's Current Assets stood at $218.5 million in 2021, then soared by 61.61% to $353.2 million in 2022, then climbed by 19.37% to $421.5 million in 2023, then retreated by 18.56% to $343.3 million in 2024, then plunged by 56.04% to $150.9 million in 2025.
• The last three Current Assets figures came in at $150.9 million (Q4 2025), $182.1 million (Q3 2025), and $231.6 million (Q2 2025), per Business Quant data.